Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.93B 5.28B 4.89B 4.45B 8.35B 562B 8.49B 58.7B 23.08B 294B 22.24B 21.77B 939B P/E 2026 *
56.4x
P/E 2027 * 34.6x
Enterprise Value 5.93B 5.28B 4.89B 4.45B 8.35B 562B 8.49B 58.7B 23.08B 294B 22.24B 21.77B 939B EV / Sales 2026 *
20.5x
EV / Sales 2027 * 15.5x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.59%
1 week-4.45%
Current month-4.83%
1 month+4.86%
3 months-2.01%
6 months+28.24%
Current year+57.23%
1 week 292.28
Extreme 292.28
307.11
1 month 281.74
Extreme 281.7401
317.23
Current year 175.89
Extreme 175.89
326.63
1 year 175.89
Extreme 175.89
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 A Exercice

General Counsel

5,680 0.0285%
9/22/26 A Tax

Director

-115 0.0006%
9/10/26 A Sell

Director

-1,200 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%-4.45%+63.66%+463.24% 5.93B
-1.33%+4.88%+54.50%+109.94% 1,106B
-0.69%-3.77%+31.35%+66.62% 612B
-0.96%+0.55%+23.13%+94.26% 500B
+1.53%+7.31%+37.35%+61.55% 367B
-1.59%-1.25%+69.39%+43.02% 354B
+0.92%+5.16%+20.47%+47.95% 286B
+0.44%+4.71%-0.86%+19.42% 256B
-1.75%+1.76%+42.21%+51.44% 230B
-2.00%+1.75%+24.64%+95.14% 190B
Average +0.42%+1.47%+36.58%+105.26% 390.61B
Weighted average by Cap. +0.77%+2.29%+38.32%+76.43%

Financials

2026 *2027 *
Net sales 289M 258M 239M 217M 407M 27.39B 414M 2.86B 1.13B 14.32B 1.08B 1.06B 45.77B 382M 340M 315M 287M 538M 36.19B 547M 3.78B 1.49B 18.91B 1.43B 1.4B 60.46B
Net income 113M 100M 92.9M 84.47M 158M 10.67B 161M 1.11B 438M 5.57B 422M 413M 17.82B 188M 167M 155M 141M 264M 17.79B 269M 1.86B 731M 9.3B 704M 689M 29.73B
Net Debt - -
Projected Income Statement - Annual - Ligand Pharmaceuticals Incorporated
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
19/10/26 $297.28 +0.59% 116,995
16/10/26 $295.54 -0.99% 164,510
15/10/26 $298.50 +1.19% 332,111
14/10/26 $294.99 -2.81% 245,284
13/10/26 $303.53 -2.44% 196,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ligand Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
297.28USD
Average target price
345.75USD
Spread / Average Target
+16.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ligand Pharmaceuticals Incorporated
  1. Stock Market
  2. Stocks
  3. LGND Stock